Debiopharm Group has plans to expand and optimize activities at Debiopharm Research & Manufacturing S.A., its development and production facility in Martigny, Switzerland, through the acquisition of industrial high-value added activities or companies in the pharma, biopharma or medical technology field.
Debiopharm Research & Manufacturing provides chemical synthesis, formulation development and manufacturing. The company aims to acquire opportunities for optimization and production of complex pharmaceutical products, with modern infrastructure combined with high-tech GMP production, a logistic platform for worldwide delivery, established quality assurance and regulatory certification, as well as a central location in Europe.
"We want to be the bridge between development and industrialization, and supply Swiss-made products manufactured using state-of-the-art technology, said Cedric Sager, chief executive officer of Debiopharm Research & Manufacturing. “Hard-to-make drugs, highly complex formulated drugs, biologic niche products, premium diagnostics and medical devices are on our wish-list."
Thierry Mauvernay, delegate of the board of Debiopharm Group, said, "We have invested heavily during the last years to automate our site in Martigny as much as possible. Thanks to our efforts, we have increased our productivity. Our wish now is to acquire new industrial opportunities to strengthen our activity in Valais and support our development.”